DISC-0998 — Topline data
H2 2026
Phase 2 data expected H2 2026Source filing
IRON biotech catalysts & pipeline
DISC MEDICINE INC · Data as of 2026-09-08
Upcoming catalysts
DISC-3405 — Initial data
Q3 2026
• Completed enrollment for RESTORE-PV Phase 2 study in patients with polycythemia vera with initial data expected in Q3 2026Source filing
selcodebart (DISC-0974) — FDA meeting
year-end
• Additional data from RALLY-MF anticipated in Q4 2026, with an end-of-Phase 2 meeting with the FDA expected to occur by year-endSource filing
bitopertin — Topline data
Q4 2026
On track to report APOLLO topline results in Q4 2026 and expect to submit CRL response and receive an FDA decision by mid-2027Source filing
DISC-3405 — Topline data
Q4 2026
Progressing ongoing Phase 2 study of DISC-3405 in polycythemia vera (PV) and Phase 1b study of DISC-3405 in sickle cell disease (SCD), with data from both studies expected in Q4 2026Source filing
selcodebart (DISC-0974) — Topline data
Q4 2026
We expect to share additional data in the fourth quarter of 2026.Source filing
selcodebart (DISC-0974) — Initial data
2027
• Progressing Phase 2 study in patients with inflammatory bowel disease (IBD) with initial data expected in 2027Source filing
bitopertin — PDUFA
mid-2027
• On track to report APOLLO topline results in Q4 2026 and expect to submit CRL response and receive an FDA decision by mid-2027Source filing
bitopertin — Regulatory decision
mid-2027
On track to report APOLLO topline results in Q4 2026 and expect to submit CRL response and receive an FDA decision by mid-2027Source filing